Unibest

Pharmaceutical intermediates

Larotrectinib Intermediates

1 pharmaceutical intermediate for Larotrectinib. Indication: Solid tumours.

提交项目All intermediates

About Larotrectinib

Originator
Bayer Healthcare Pharmaceuticals Inc
Indication
Solid tumours
Approved Date
11/26/2018
DS/DP
11/21/2029

Available intermediates

1 intermediate currently listed for Larotrectinib. Request specifications, documentation or a quotation for any item below.

Larotrectinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(R)-2-(2,5-Difluorophenyl)pyrrolidine D-malate1919868-77-1//

Other programs under L

(LCZ696)LanifibranorLapatinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodiumLenalidomide

Building toward Larotrectinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →